Clinical implications of the new biology in the development of melanoma vaccines

Journal of Surgical Oncology

Volumn 70, Issue 4, 1999, Pages 263-274

  Hemmila, Mark R ^b   Chang, Alfred E ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Gene therapy; Immunotherapy; Melanoma; Tumor antigens; Vaccine

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA2B INTERFERON; BCG VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 4; LEVAMISOLE; MELANOMA VACCINE; METHISOPRINOL; THYMOSTIMULIN; THYMUS FACTOR; TRANSFER FACTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ANTIGEN PRESENTATION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INTRADERMAL DRUG ADMINISTRATION; MELANOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, CD8; BCG VACCINE; CANCER VACCINES; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-B7 ANTIGEN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032953891     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199904)70:4<263::AID-JSO14>3.0.CO;2-1     Document Type: Review

References (98)

1. Conforti AM, Ollila DW, Kelley MC, et al.: Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 1997;66:55-64.
2. Cerottini JC, Liénard D, Romero P: A new era for human cancer immunology. Immunologist 1997;27-31.
3. Morton DL, Malmgren RA, Holmes EC, et al.: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968;64:233-240.
4. Morton DL, Eilber FR, Malmgren RA, et al.: Immunological factors which influence responses to immunotherapy in malignant melanoma. Surgery 1970;68:158-164.
5. Mukherji B, Chakraborty NG, Sivanandham M: T-cell clones that react against autologous human tumors. Immunol Rev 1990;116: 33-62.
6. Topalian SL, Solomon D, Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3614-3725.
7. Rosenberg SA, Yannelli JR, Yang JC, et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Nat Cancer Inst 1994;86:1159-1166.
8. Chang AE, Hynds Kamell L, Menck HR: The National Cancer Data Base report on cutaneous and non-cutaneous melanoma: A summary of 84,836 cases from the past decade. Cancer 1998;83: 1664-1678.
9. Cunningham TJ, Schoenfeld D, Nathanson L, et al.: A controlled ECOG study of adjuvant therapy in patients with stage I & II melanoma. In Jones SE, Salmon SE (eds): "Adjuvant Therapy of Cancer II." New York: Grune & Stratton, 1979: 507.
10. Kaiser LR, Burk MW, Morton DL: Adjuvant therapy for malignant melanoma. Surg Clin N Am 1981;61:1249-1257.
11. Pinsky CM, Oettgen HF: Surgical adjuvant therapy for malignant melanoma. Surg Clin N Am 1981;61:1259-1266.
12. Fisher RI, Terry WD, Hodes RJ, et al.: Adjuvant immunotherapy or chemotherapy for malignant melanoma: Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin N Am 1981;61:1267-1277.
13. Veronesi U, Adamus J, Aubert C, et al.: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-916.
14. Paterson AH, Willans DJ, Jerry LM, et al.: Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J 1984;131: 744-748.
15. Karakousis CP, Emrich LJ: Adjuvant treatment of malignant melanoma with DTIC + Estracyt or BCG. J Surg Oncol 1987;36: 235-238.
16. Quirt IC, Shelley WE, Pater JL, et al.: Improved survival in patients with poor-prognosis malignant melanoma treatment with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991;9: 729-735.
17. Czarnetzki BM, Macher E, Suciu S, et al.: Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993;29A:1237-1242.
18. Truchetet F, Heid E, Friedel J, et al.: D.N.C.B. for malignant melanoma: significance in the treatment strategy. Anticancer Res 1989;9:1531-1536.
19. Lukacs L, Istvan M: Immunosurgical approach to the treatment of malignant melanoma using 2,4-dinitrochlorobenzene (DNCB). Neoplasma 1984;31:437-445.
20. Sondak VK, Wolfe JA: Adjuvant therapy for melanoma. Curr Opin Oncol 1997;9:189-204.
21. Tai T, Paulson JC, Cahan LD, et al.: Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Nat Acad Sci USA 1983;80:5392-5396.
22. Cahan LD, Irie RF, Singh R, et al.: Identification of a human neuroectodermal tumor antigen (OFA-1-2) as ganglioside GD2. Proc Nat Acad Sci USA 1982;79:7629-7633.
23. Cheresh DA, Varki AP, Varki NM, et al.: A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem 1984;259:7453-7459.
24. Traversari C, van der Bruggen P, Luescher IF, et al.: A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
25. van der Bruggen P, Bastin J, Gajewski T, et al.: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocyte that recognize tumor cells expressing MAGE-3, Eur J Immunol 1994;24:3038-3043.
26. Boel P, Wildmann C, Sensi ML, et al.: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995:2:167-175.
27. Van den Eynde B, Peelers O, De Backer O, et al.: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698.
28. Kawakami Y, Eliyahu S, Sakaguchi K, et al.: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
29. Bakker AB, Schreurs MW, Tafazzul G, et al.: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 1995;62:97-102.
30. Skipper JC, Kittlesen DJ, Hendrickson RC, et al.: Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996;157:5027-5033.
31. Wang RF, Robbins PF, Kawakami Y, et al.: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A3I restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181:799-804.
32. Brichard V, Van Pel A, Wolfel T, et al.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
33. Kang X, Kawakami Y, el-Gamil M, et al.: Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-1348.
34. Brichard VG, Herman J, Van Pel A, et al.: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996;26: 224-230.
35. Topalian SL, Gonzales MI, Parkhurst M. et al.: Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996;183:1965-1971.
36. Wolfel T, Hauer M, Schneider J, et al.: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
37. Aruga A, Aruga E, Tanigawa K, et al.: Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997:159:664-673.
38. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F: A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998:160:5869-5873.
39. + T-help and T-killer cell. Nature 1998;393:474-488.
40. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 1988;6:337-349.
41. Berd D, Maguire HC, McCue P, et al.: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-1867.
42. Fujiwara H, Aoki H, Yoshioka T, et al.: Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system. J Immunol 1984;133:509-514.
43. Berd D, Murphy G, Maguire HC Jr, et al.: Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 1991;51:2731-2734.
44. Berd D, Maguire HC, Schuchter LM, et al.: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359-2370.
45. Sato T, Bullock TNJ, Eisenlohr LC, et al.: Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clin Immunol Immunopathol 1997;85:265-272.
46. Morton DL, Foshag LJ, Hoon DS, et al.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
47. Morton DL, Nizze A, Hoon D, et al.: Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine. Proc Am Soc Clin Oncol 1993; 12:391.
48. Morton DL, Barth A: Vaccine therapy for malignant melanoma. Can Cancer J Clin 1996;46:225-244.
49. Jones RC, Kelley M, Gupta RK, et al.: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Ann Surg Oncol 1996;3:437-445.
50. Hsueh EC, Gupta RK, Qi K, et al.: TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997;3:364-370.
51. Wallack MK, Bash JA, Leftheriotis E, et al.: Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987;122:1460-1463.
52. Wallack MK, Sivanandham M, Ditaranto K, et al.: Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: Second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997:226:198-206.
53. Wallack MK, Sivanandham M, Balch CM, et al.: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J AmColl Surg 1998; 187:69-77.
54. Hersey P: Active immunotherapy with viral lysates of microme-tastases following surgical removal of high risk melanoma. World J Surg 1992; 16:251-260.
55. Hersey P: Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann NY Acad Sci 1993;690: 167-177.
56. Hersey P: Melanoma vaccines: Current status and future prospects. Drugs 1994;47:373-382.
57. Mitchell MS, Kan-Mitchell J, Kempf RA, et al.: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-5893.
58. Mitchell MS, Harel W, Kan-Mitchell J, et al.: Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-166.
59. Mitchell MS, Harel W, Kempf RA, et al.: Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-869.
60. Mitchell MS, Jakowatz J, Harel W, et al.: Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-411.
61. Mitchell MS, Rechtman DJ, Von Eschen KB: A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 1995;6(suppl C): 347C.
62. Fearon ER, Pardoll DM, Itaya T, et al: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
63. Golumbek PT, Lazenby AJ, Levitsky HI, et al.: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-716.
64. Strome SE, Krauss JC, Cameron MJ, et al.: Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma. Arch of Otol 1993:119:1289-1295.
65. Dranoff G, Jaffe E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sci USA 1993;90: 3539-3543.
66. Porgador A, Tzehoval E, Katz A, et al.: Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-3686.
67. Dranoff G, Soiffer R, Lynch M, et al.: A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor, Human Gene Ther 1997;8:111-123.
68. Ellem KA, O'Rourke MG, Johnson GR, et al.: A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997;44:10-20.
69. Nemunaitis J, Bohart C, Fong T, et al.: Phase I trial of retroviral vector-mediated Interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther 1998;5:292-300.
70. Abdel-Wahab Z, Weltz C, Hester D, et al.: A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 1997;80:401-412.
71. Livingston PO, Wong G, Adluri S, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
72. Rosenberg SA, Yang JC, White DE, Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2; Identification of the antigens mediating response. Ann Surg 1998;228:307-319.
73. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
74. Aebersold PM, Hyatt C, Johnson S, et al.: Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: Association with clinical response. J Nat Cancer Inst 1991;83:932-937.
75. Pardoll DM: Tumour antigens: a new look for the 1990s. Nature 1994;369:357-358.
76. Celluzzi CM, Mayordomo JI, Storkus WJ, et al.: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
77. Grabbe S, Beissert S, Schwarz T, et al.: Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-121.
78. Lotze MT: Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 1997; 226:1-5.
79. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179:1109-1118.
80. + blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-1471.
81. + progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of Melan-A/Mart-1(27-35) specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997;57:5534-5541.
82. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995; 1:1297-1302.
83. Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998:4:328-332.
84. Reeves ME, Royal RE, Lam JS, et al.: Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996;56:5672-5677.
85. Henderson RA, Nimgaonkar MT, Watkins SC, et al.: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-I). Cancer Res 1996;56:3763-3770.
86. Bronte V, Tsung K, Rao JB, et al.: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-5292.
87. Kurzawa H, Wysocka M, Aruga E, et al.: Recombinant interleukin-12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 1998;58:491-499.
88. Plautz GE, Yang ZY, Wu GY, et al.: Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Nat Acad Sci USA 1993;90:4645-4649.
89. Nabel GJ, Nabel EG, Yang ZY, et al.: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Nat Acad Sci USA 1993;90:11307-11311.
90. Nabel GJ, Gordon D, Bishop DK, et al.: Immune response in human melanoma transfer of an allogeneic class I major histo-compatability complex gene with DNA-liposome complexes. Proc Nat Acad Sci USA 1996;93:15388-15393.
91. Turner JG, Tan J, Crucian BE, et al.: Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Human Gene Ther 1998;9:1121-1130.
92. Geiger JD, Wagner PD, Shu S, Chang AE: A novel role of autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1992;1: 199-208.
93. Geiger JD, Wagner PD, Cameron MJ, et al.: Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 1993;13:153-165.
94. Wahl WL, Strome SE, Nabel GJ, et al.: Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompability complex gene. J Immunother 1995; 17:1-11.
95. Chang AE, Aruga A, Cameron MJ, et al.: Adoptive immunotherapy with vaccine-primed lymph node cell secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997:15:796-807.
96. Area MJ, Krauss JC, Aruga A, et al.: Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulcotye-macrophage colony-stimulating factor. Cancer Gene Ther 1996;3:39-47.
97. Area MJ, Krauss JC, Strome SE, et al.: Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996;42:237-245.
98. Chang AE, Sondak VK, Bishop DK, et al.: Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Human Gene Ther 1996;7:773-792.